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 Patients with COPD regularly experience walking as a problematic activity in everyday life. 1 Indeed, 
patients walk less and at a lower intensity in daily 
life compared with their healthy peers. 2 Moreover, 
patients with COPD have a severely reduced functional 
exercise capacity as assessed by the 6-min walk test 
(6MWT), 3-5 which contributes to a higher exacerbation-
related hospitalization risk, a reduced quality of life, 
and a worse prognosis. 6 
 Ambulation aids (ie, rollators [ Fig 1A ] ) can contrib-
ute to independent living and safe mobility, although 
strength and metabolic demands can be excessive. 7 
The use of a rollator generally results in clinically 
relevant improvements in 6-min walk distance (6MWD) 
of 22 to 46 m compared with an unaided 6MWD, 
particularly in sedentary patients with COPD. 8-11 
This is at least in part due to an increase in maximal 
voluntary ventilation of about 10% while using a 
rollator compared with not using an ambulation aid. 10 
Indeed, by bracing their arms on the rollator, patients 
with COPD can adopt the “forward-lean” position, 
which may improve diaphragm function and, therefore, 
 Background:  Generally, the use of a rollator improves mobility in patients with COPD. Neverthe-
less, not all patients benefi t from its use, and many patients feel embarrassed about using it. 
Therefore, other walking aids are worthwhile to consider. We compared the direct effects of a 
“new” ambulation aid (a modern draisine) with the effects of a rollator on 6-min walk distance 
(6MWD) in patients with COPD. 
 Methods:  Twenty-one patients with COPD performed two 6-min walk tests (6MWTs) during pre-
rehabilitation assessment (best 6MWD: 369   88 m). Additionally, two extra 6MWTs were per-
formed on two consecutive days in random order: one time with a rollator and one time with a 
modern draisine. Walking pattern (n  5 21) was determined using an accelerometer, and meta-
bolic requirements (n  5 10) were assessed using a mobile oxycon. 
 Results:  Walking with the modern draisine resulted in a higher 6MWD compared with walking 
with the rollator (466   189 m vs 383   85 m). Moreover, patients had fewer strides (245   61 
vs 300   49) and a greater stride length (1.89   0.73 m vs 1.27   0.14 m) using the modern draisine 
compared with the rollator (all  P   .001). Oxygen uptake, ventilation, heart rate, oxygen satura-
tion, and Borg symptom scores were comparable between both walking aids. Ten percent of the 
patients felt embarrassed using the modern draisine compared with 19% for the rollator, and a 
signifi cantly smaller proportion of patients would use the modern draisine in daily life. 
 Conclusions:  The mean difference in 6MWD between a modern draisine and a rollator seems 
clinically relevant, with the same metabolic requirements and symptom Borg scores. Therefore, 
this “new” ambulation aid could be a good alternative to the rollator to improve functional exer-
cise performance in patients with COPD. 
 Trial registry:  The Netherlands National Trial Registry; No.: NTR1542; URL: www.trialregister.nl 
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 Abbreviations:  6MWD  5 6-min walk distance; 6MWT  5 6-min walk test 
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 Materials and Methods 
 Design 
 The study followed a prospective, randomized, crossover design. 
Patients were eligible to participate when they had been given 
a diagnosis of COPD, had a 6MWD   500 m (see the “Study 
Protocol” section for details), and had had no acute COPD exac-
erbation in the previous 4 weeks. Patients suffering from a muscu-
loskeletal, cardiovascular, or neurologic disorder were excluded. 
All subjects gave written informed consent to participate in the 
study, which was approved by the medical ethical committee of 
the Maastricht University Medical Centre (MEC 08-3-069). The 
current project was registered on www.trialregister.nl (NTR1542) 
before enrollment of the fi rst volunteering participant. 
 Study Protocol 
 Patients were recruited by A. W. V. and M. W. J. C. at CIRO 1 . 20 
During routine prerehabilitation assessment, pulmonary func-
tion and body composition were determined as described ear-
lier. 3 A symptom-limited cardiopulmonary exercise test on a cycle 
ergometer (Ergoline 200P; Ergoline GmbH) was used to deter-
mine peak aerobic capacity and was performed according to 
international guidelines. 21 In addition, functional exercise per-
formance, including a practice walk. was determined using the 
6MWT as described by the latest American Thoracic Society 
guidelines. 22,23 Only patients with a 6MWD   500 m were eligible 
to participate in the current study, because these patients are 
expected to benefi t the most from the use of ambulation aids. 15 
 Eligible patients were asked to perform two additional 6MWTs 
in a triangular walking course of 125 m on two consecutive week-
days. Patients were randomly assigned, using sealed envelopes 
(made by M. A. S.), to do a 6MWT with a rollator on day 1 
( Fig 1A ), followed by a 6MWT with the modern draisine on day 2 
( Fig 1B ), or vice versa. See e-Appendix 1 for specifi cations and 
settings for both ambulation aids. 
 All patients were familiarized with both ambulation aids 
through verbal instructions, in combination with a practice session of 
10 min by M. W. J. C. The familiarization procedure was set up 
in close collaboration with an experienced occupational therapist 
(J. W.). M. W. J. C. supervised all additional aided 6MWTs, which 
were also performed in accordance with American Thoracic Society 
guidelines. 22 At the end of the 6MWTs, patients were asked to 
complete a questionnaire about their preference for and confi dence 
in and the safety of the ambulation aid (e-Appendix 1). 
 Outcomes 
 Primary outcome was the difference in 6MWD (in meters) 
between the modern draisine and the rollator. In addition, several 
explanatory outcomes were assessed: the number of assessor-
initiated stops (based on an exercise-induced oxygen satura-
tion  , 80%), transcutaneous oxygen saturation, heart rate, Borg 
symptom scores for dyspnea and fatigue 24 before and after each 
6MWT and after 2 min of recovery, metabolic requirements 
during each 6MWT, number of strides, stride length, root mean 
square of the acceleration in mediolateral direction, walk ratio, 
and patient’s preference for and confi dence in the ambulation aid. 
See e-Appendix 1 for details. 
 Statistics 
 Data are presented as mean and SD, unless noted otherwise. 
The paired-samples  t test was used to assess differences between 
the use of the rollator and the modern draisine. A priori, the level 
of signifi cance was set at   .05. No adjustment was made to the 
statistical signifi cance level for multiple comparisons. All data were 
analyzed with SPSS, version 17.0 (SPSS Inc). 
increase ventilatory capacity. 12 This may also explain 
why rollator use is effective in relieving exercise-
induced dyspnea in patients with COPD and advanced 
disease. 13,14 
 On average, a rollator is benefi cial for patients 
with COPD, 15 yet not all patients benefi t from its 
use. 8,10,16 Moreover, 48% of the patients with COPD 
using a rollator feel embarrassed about its use in daily 
life. 17 Therefore, other ambulation aids may be worth-
while to consider in patients with COPD. Unfortu-
nately, the effects of unwheeled Zimmer frames 
on 6MWD are insignifi cant in elderly patients with 
COPD. 16 
 In 1817, Karl Drais invented the “Laufmaschine,” 
the earliest form of a bicycle, but without pedals, later 
also called the velocipede or draisine. 18 The modern 
version of the draisine ( Fig 1B ) may also improve 
6MWD in COPD. Indeed, by holding the handlebars 
it increases maximal voluntary ventilation and, in turn, 
6MWD, similar to the results achieved with a rollator. 10 
Moreover, by sitting on the seat of the modern 
draisine the load on the deconditioned muscles of 
ambulation is reduced. 19 In turn, this may result in 
a signifi cantly lower cost of transport (eg, milliliters 
per minute of oxygen uptake per meter), allowing 
patients with COPD to achieve a higher 6MWD with 
similar effort. 
 To date, the direct effects of this “new” ambulation 
aid on 6MWD remain unknown in patients with COPD. 
Prospectively, we sought to determine whether the 
modern draisine had similar direct effects on 6MWD 
as those of a rollator in patients with COPD. More-
over, we aimed to assess walking pattern, exercise-
induced symptoms, metabolic requirements using 
both ambulation aids, and patient satisfaction using 
both ambulation aids. 
 Manuscript received April 28, 2011; revision accepted November 1, 
2011. 
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6MWTs, whereas 11 patients (52%) used long-term 
oxygen therapy. Therefore, data on metabolic require-
ments are available in 10 patients with COPD. Patients 
receiving long-term oxygen therapy transported their 
oxygen in the basket of the rollator or the modern 
draisine. 
 Effects of Ambulation Aids on 6MWD 
 On average, 6MWT with the modern draisine 
resulted in a signifi cantly higher 6MWD compared with 
6MWT with the rollator (466   189 m vs 383   85 m, 
 P  5 .011) ( Table 2 ), with no signifi cant differences 
between patients who had already used a rollator 
before and those who had walked unaided ( Fig 3 ). 
 Patients with COPD who did not use a rollator at 
baseline had a baseline 6MWD of 384   90 m. Use of 
a rollator resulted in a signifi cantly higher 6MWD 
compared with baseline (402   83 m,  P  5 .040). More-
over, using the modern draisine resulted in a mean 
6MWD of 501   200 m, which was signifi cantly higher 
than baseline 6MWD ( P  5 .024) and rollator-aided 
6MWD ( P  5 .038). 
 Effects of Ambulation Aids on 
Exercise-Induced Symptoms 
 No signifi cant differences were found between 
6MWT with the rollator or the modern draisine in 
Borg symptom scores for dyspnea and fatigue at the 
start of 6MWT, at the end of 6MWT, or after 2 min 
recovery ( Table 2 ). Moreover, the number and duration 
of patient-initiated stops were comparable between 
both ambulation aids ( Table 2 ). The main reason for 
patient-related stops was dyspnea. Other reasons 
were fatigue and/or pain in shoulders/arms, foot, os 
sacrum, or lower back. There were no assessor-initiated 
stops. 
 Effects of Ambulation Aids on 6MWD 
Walking Pattern 
 The use of the modern draisine resulted in sig-
nificantly fewer strides compared with the rollator 
(245   61 vs 300   49,  P  5 .001). Consequently, patients 
had a signifi cantly lower stride frequency and a greater 
stride length with the modern draisine compared with 
the rollator ( P  5 .001) ( Table 2 ). Moreover, the walk 
ratio was signifi cantly higher and the root mean square 
in the mediolateral direction was signifi cantly lower 
while using the modern draisine compared with the 
rollator ( P  5 .001). 
 Effects of Ambulation Aids on 
Metabolic Requirements 
 Oxygen uptake, ventilation, heart rate, and oxygen 
saturation before and directly after the 6MWT were 
 Results 
 One hundred fi fteen of the 158 subjects who were 
screened between January 2009 and January 2011 
were ineligible to participate for various reasons (see 
 Figure 2 for details). In addition, 15 eligible subjects 
declined participation because of lack of interest, 
dyspnea, or fatigue. The characteristics of these patients 
were not signifi cantly different from those enrolled in 
this study. Of the remaining 28 eligible patients with 
COPD, seven were excluded (one before the per-
formance of the two aided 6MWTs and six after the 
performance of the fi rst aided 6MWT) because of the 
onset of symptoms of an acute COPD exacerbation 
(n  5 4), orthopedic problems (n  5 2), or malfunction-
ing of the measurement system that collected the gait 
pattern information (n  5 1). Finally, 21 patients with 
COPD completed both aided 6MWTs. 
 Patient Characteristics 
 On average, patients had moderate to very severe 
COPD, a normal BMI, and a normal fat-free mass 
index ( Table 1 ). The best 6MWD during routine prere-
habilitation assessment was 369   88 m. Eight patients 
(38%) used a rollator during routine prerehabilitation 
  
 Figure 1. Walking aids. A, Rollator. B, Modern draisine. 
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feeling of falling was signifi cantly lower while using 
the rollator ( P  , .05). No signifi cant differences were 
found in scores for safety and confi dence between 
the rollator and the modern draisine. 
 Discussion 
 The current study has three important fi ndings. 
First, ambulation aids generally improve functional 
exercise performance in patients with COPD. Second, 
the use of the modern draisine may result in clinically 
relevant improvements in 6MWD in patients with 
COPD as compared with a rollator-aided 6MWT, 
whereas the metabolic requirements and exercise-
related symptoms are comparable. Third, clear dif-
ferences in gait pattern were observed between the 
modern-draisine-aided 6MWT and the rollator-aided 
6MWT, resulting in a lower cost of transport for the 
modern draisine compared with the rollator. This par-
tially explains the difference in 6MWD. 
 Previous studies have already shown that the use 
of a rollator during 6MWT is associated with a sig-
nificant improvement in walking distance of 22 to 
46 m. 8-10,25 To the best of our knowledge, this study is 
the fi rst to compare the effects of a rollator on 6MWD 
with those of a “new” walking frame in patients with 
comparable between ambulation devices, as well as 
after 2 min of recovery ( Table 3 ). Because of the 
longer walking distance, use of the modern draisine 
resulted in a signifi cantly lower cost of transport 
(oxy gen uptake per meter) compared with use of 
the rollator (0.10 [0.03] vs 0.14 [0.03] mL/min/m, 
 P  , .05). 
 Level of Acceptance With Use of Ambulation Aids 
 Sixty-two percent of the patients with COPD had 
never used a rollator before in daily life or during 
6MWT, but 81% liked the rollator and 76% would use 
it in daily life. Nineteen percent of the patients with 
COPD felt embarrassed using the rollator ( Table 4 ). 
 None of the patients had ever used the modern 
draisine. Although only 10% of the subjects felt embar-
rassed using the modern draisine, signifi cantly fewer 
patients (38%) would like to use the new ambula-
tion aid in their daily life, compared with a rollator 
( P  , .05). Furthermore , signifi cantly more patients 
believed they walked further than during unaided 
6MWT while using rollator compared with the mod-
ern draisine ( P  , .01). 
 Patients with COPD gave signifi cantly higher scores 
for the stability and solidity of the rollator compared 
with the modern draisine ( P  , .05). Moreover, the 
 Figure 2. Disposition of patients. 
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COPD. The mean difference in 6MWD between the 
modern draisine and the rollator clearly exceeded 
the upper limit of the 95% CI (61 m) of the updated 
minimal clinically important difference of 6MWD 
as proposed by Holland et al. 11 Indeed, occupational 
therapists may want to consider the use of the mod-
ern draisine to augment the mean improvement in 
6MWD of 50 m following exercise-based pulmonary 
rehabilitation. 20 
 None of the patients with COPD had used the 
modern draisine before. Therefore, all patients had 
a practice walk of 10 min with each ambulation aid. 
This may be too short for proper familiarization. 
Some patients reported having problems with their 
balance during the extra 6MWTs. Indeed, six subjects 
walked 17 to 135 m less with the modern draisine 
compared with the rollator in the 6MWT ( Fig 3 ). 
Then again, one patient had pain in the os sacrum 
due to an accidental fall one day before the draisine-
aided 6MWT, which made sitting on the seat of the 
draisine painful, and another patient bumped her 
foot on the bike, resulting in pain during the 6MWT. 
Because the rollator and the modern draisine were 
adapted to the size of the patients (e-Appendix 1), 
balance problems were not caused by incorrect 
adjustment of the ambulation aids. However, a rol-
lator is a stable ambulation aid, whereas the modern 
draisine needs the active support of the user to remain 
stable and to avoid falling. Therefore, a 6MWT with 
the modern draisine could result in a feeling of 
less safety in terms of balance and falling. This may 
improve when patients are able to practice more 
frequently or for a longer period ( . 10 min). 
 Previously, Probst and colleagues 10 investigated the 
direct effects of the use of a rollator on metabolic 
requirements in patients with COPD. They found an 
average oxygen uptake of 1.0 L/min and a ventilation 
of 34 L/min in patients during a rollator-aided 6MWT. 
This is very consistent with our results. Indeed, walk-
ing with the rollator resulted in a mean oxygen uptake 
of 0.9 L/min and a mean ventilation of 34.8 L/min 
compared with a mean oxygen uptake of 0.9 L/min 
and a mean ventilation of 35.3 L/min when walking 
with the modern draisine. Differences in overall meta-
bolic requirements between the two ambulation aids 
were not signifi cant. However, while using the mod-
ern draisine, patients with COPD walked, on average, 
83 m further with the same oxygen uptake, ventila-
tion, and heart rate compared with walking with a 
rollator ( Tables 2, 3 ). In patients with COPD, there-
fore, the use of the modern draisine resulted in a 
greater walking distance with the same energy use 
and metabolic demands, which could be considered 
an improvement in walking economy. 
 Table 1— Baseline Characteristics (N  5 21) 
Characteristics Value
Demographics
 Men, % 52.4
 Age, y 64.2 (10.1)
Pulmonary function
 FEV 1 , L 1.1 (0.3)
 FEV 1 , % predicted 42.0 (15.0)
 FEV 1 /FVC, % 37.3 (10.2)
 GOLD stage I/II/III/IV, No. 0/3/9/9
 MRC grade 1/2/3/4/5, No. 1/2/6/5/7
Body composition
 BW, kg a 66.0 (19.0)
 BMI, kg/m 2 23.5 (5.3)
 FFM, kg 45.7 (9.9)
 FFM, kg/m 2 16.3 (2.2)
6MWD, m 369 (88.0)
 Borg dyspnea, points 5.4 (2.2)
 Borg fatigue, points 4.4 (2.3)
Cardiopulmonary exercise test
 Peak   o 2 , mL/min 902 (284)
 Peak   o 2 , mL/min/kg BW 13.9 (4.4)
 Peak  e , L 37.9 (8.8)
 Peak  e , % MVV 88.7 (17.9)
 Peak HR, bpm 122.2 (22.3)
 Peak HR, % max HR 79.9 (17.5)
 Borg dyspnea, points 7.1 (1.8)
 Borg fatigue, points 5.9 (2.4)
Data are presented as mean (SD) unless indicated otherwise. 
6MWD  5 6-min walk distance; bpm  5 beats per minute; BW  5 body 
weight; FFM  5 fat-free mass; GOLD  5 Global Initiative for Chronic 
Obstructive Lung Disease HR  5 heart rate; MRC 5 Medical Research 
Council; MVV  5 maximal voluntary ventilation;  e  5 minute ventilation ; 
  o 2  5 oxygen uptake.
 a 1 kg  5 2.2046 lb.
 Table 2— Effects of Ambulation Aids (N  5 21 ) 
Variables Rollator
Modern 
Draisine  P Value
6MWD, m 382.8 (84.7) 465.9 (188.5) .011
Strides, No. 300.3 (49.1) 245.3 (60.9) .001
Stride length, m 1.27 (0.14) 1.89 (0.73) .001
Stride frequency, strides/s 0.88 (0.11) 0.76 (0.14) .001
Number of stops 0.50 (0.68) 0.62 (0.86) .186
Total duration of stops, s 20.5 (29.9) 25.9 (35.0) .297
Walk ratio, m/(steps/s) 1.46 (0.22) 2.36 (1.04) .001
Acceleration RMS 0.19 (0.07) 0.10 (0.03) .001
Borg dyspnea before, points 2.0 (1.5) 1.7 (1.2) .351
Borg dyspnea after, points 4.9 (1.8) 5.1 (1.3) .620
Borg dyspnea 2 min after, 
points
3.0 (1.2) 3.3 (1.5) .377
Borg fatigue before, points 1.9 (1.8) 1.4 (1.4) .154
Borg fatigue after, points 3.6 (2.4) 3.9 (2.3) .543
Borg fatigue 2 min after, 
points
2.7 (2.0) 2.4 (1.7) .342
Sp o 2 before, % 93.4 (2.0) 93.4 (2.2) 1.000
Sp o 2 drop, %  2 8.0 (4.0)  2 8.1 (5.2) .950
Sp o 2 2 min after, % 94.2 (2.1) 94.1 (1.8) .729
Data are presented as mean (SD). RMS  5 root mean square; Sp o 2  5 satu-
ration of peripheral oxygen. See Table 1 legend for expansion of other 
abbreviations.
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 One of the main advantages of the modern draisine 
is the possibility of sitting on the seat, resulting in a 
lower load for the muscles of ambulation. This could 
explain at least partially why patients with COPD are 
able to walk further with the same metabolic demands. 
Furthermore, the modern draisine is foldable and 
lightweight (modern draisine, 9.0 kg, compared with 
the rollator, 12.4 kg), which makes it easy for every-
day use. Similar to the rollator, the modern draisine 
has a basket, which gives patients with long-term 
oxygen therapy the ability to transport their oxygen. 
The major disadvantage of the modern draisine com-
pared with a rollator is the higher cost, which is fi ve-
fold the cost of a rollator. 
 In the current study, patients with COPD had 
a higher velocity while walking with the modern 
draisine compared with walking with the rollator. 
Several studies have shown that the ratio between 
stride length and stride frequency is constant over 
a large range of walking speeds during normal walk-
ing in healthy subjects. 26,27 However, we found a sig-
nificantly higher walk ratio in patients while using 
the modern draisine. This altered pattern indicates 
that patients with COPD using the modern draisine 
walked with a greater stride length relative to stride 
frequency, probably caused by the natural tendency 
to slightly roll between steps while using the modern 
draisine. Moreover, accelerations in the mediolateral 
direction were signifi cantly lower when using the 
modern draisine compared with the rollator, which 
indicates a walking pattern with less lateral dis-
placement. This is inconsistent with the fi ndings of 
Menz and colleagues, 28 who reported previously that 
accelerations in the mediolateral direction appear 
to increase as walking speed increases. However, 
patients with COPD were able to sit on the seat of the 
modern draisine, probably resulting in a more fi xed 
center of gravity and a reduced lateral displacement. 
Therefore, the “new” ambulation aid could result 
in a more effective walking pattern in patients with 
COPD, compared with walking with the rollator. 
 Hill et al 17 showed that the use of a rollator seems 
well tolerated in the everyday life of patients with 
COPD. Patients with COPD mostly use their rollator 
for outdoor activities, such as walking, shopping, 
or recreational pursuits. 17,25 Even though a rollator 
appears to be benefi cial for patients with COPD, 
48% of the patients with COPD using a rollator feel 
embarrassed about its use in daily life. 17 In our study, 
only 19% of the patients with COPD felt embarrassed 
using the rollator, because of “a visual indication of 
disability and aging,” compared with only 10% with 
the modern draisine. Still, only 38% of the patients 
would use the new ambulation aid in their daily life. 
Whether patients’ satisfaction with their walking aid 
may improve after they have used it for a longer 
period 29 remains unknown. 
 Several methodologic limitations need to be 
addressed. For obvious reasons, it was not possible to 
blind patients or the outcome assessor to the inter-
ventions. Furthermore, because of the portable met-
abolic system, we were not able to measure patients 
with long-term oxygen therapy. Therefore, data from 
oxygen uptake, ventilation, and heart rate during 
the 6MWTs were available in only 10 patients with 
COPD. 
 Table 3— Metabolic Requirements During 
6MWT (n  5 10) 
Variables Rollator
Modern 
Draisine  P Value
  o 2 before, mL/min 304.7 (41.2) 314.5 (32.0) .308
  o 2 before, %   o 2 max 30.3 (9.0) 31.4 (9.7) .241
  o 2 at the end of 
6MWT, mL/min
946.4 (159.5) 888.9 (173.8) .600
  o 2 at the end of 
6MWT, %   o 2 max
93.6 (26.9) 90.8 (22.7) .444
  o 2 2 min after, mL/min 437.7 (88.1) 458.1 (135.0) .546
  o 2 2 min after, %  o 2 max 43.8 (16.0) 48.4 (19.5) .302
  e before, L/min 14.8 (2.9) 14.2 (2.5) .325
  e before, %   e max 38.4 (14.9) 37.0 (13.9) .311
  e at the end of 
6MWT, L/min
34.8 (6.4) 35.3 (8.2) .739
  e at the end of 
6MWT, %  e max
89.4 (24.1) 89.6 (22.8) .951
  e 2 min after, L/min 20.3 (4.6) 21.0 (7.3) .591
  e 2 min after, %  e max 53.1 (21.9) 55.1 (26.6) .521
HR before, bpm 84.6 (10.6) 85.7 (12.2) .459
HR before, % HRmax 70.2 (12.2) 71.1 (12.6) .472
HR at the end of 
6MWT, bpm
107.5 (12.2) 110.4 (14.3) .341
HR at the end of 
6MWT, % HRmax
90.1 (10.8) 92.1 (12.2) .290
HR 2 min after, bpm 90.1 (12.9) 97.8 (9.9) .128
HR 2 min after, % HRmax 75.5 (12.8) 81.8 (11.2) .109
Data are presented as mean (SD). 6MWT  5 6-min walk test. See 
Table 1 legend for expansion of other abbreviations.
 Figure 3. 6MWD in patients with COPD using rollator vs mod-
ern draisine. 6MWD  5 6-min walk distance (in meters); 6MWT  5 
6-min walk test. 
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 The use of walking aids can result in clinically 
relevant increases in 6MWD in patients with COPD 
( Table 2 ), which may improve their everyday mobil ity. 
Then again, the observed increase in 6MWD due to 
the use of ambulation aids can only be considered an 
increase in functional exercise performance; it cannot be 
considered a real improvement in functional exercise 
capacity (eg, as seen after pulmonary rehabilitation). 32 
 The proportion of patients with feelings of embar-
rassment about the use of ambulation aids was rather 
low ( Table 4 ). This may be because the tests were 
performed in a clinical context. Numbers most prob-
ably increase when the tested walking aids are used in 
daily life. 17 The questionnaire used to assess patients’ 
satisfaction was not validated. Future trials should 
consider use of the Quebec User Evaluation of Satis-
faction with Assistive Technology. 33 
 Finally, the current fi ndings need to be interpreted 
in light of the number of comparisons that were 
made in the study. Nonetheless, multiple fi ndings in 
the same direction, rather than a single statistically 
significant result, suggest that these are not due 
to chance alone. Moreover, “Bonferoni adjustments 
are at best, unnecessary and, at worst, deleterious 
to sound statistical inference.” 34 
 Previously, unaided 6MWD cutoffs of 300 to 400 m 
have been suggested to identify patients with COPD 
who may benefi t from a rollator. 8,10 Nevertheless, 
to the best of our knowledge, the current trial is 
the fi rst to study the effects of the draisine in patients 
with COPD. Therefore, we decided to set a base-
line 6MWD of 500 m as the upper limit for inclu-
sion. In fact, seven of nine patients with a baseline 
6MWD  . 400 m walked further with the draisine 
compared with the rollator ( Fig 3 ). 
 In this study, the 6MWTs were conducted indoors 
on a fl at surface. Indeed, it can be questioned if the 
modern draisine can be used indoors . However, 
earlier studies have shown that a rollator is often used 
for outside activities. 17,25 Moreover, patients with 
COPD frequently reported outdoor walking as a 
problematic activity of daily life. 30 Therefore, future 
studies are needed to compare the effects of the 
modern draisine with those of the rollator during 
outdoor walking, using a self-paced walking test. 31 
Because of the larger wheel size, the benefi ts of the 
modern draisine may emerge to be even better when 
used outdoors. This may also show that patients are 
able to walk at a similar speed but for a longer period 
while using a modern draisine. 
 Table 4— Data From Questionnaire 
Question Rollator (n  5 21) Modern Draisine (n  5 21)
Used before in daily life? 8 0 a 
Used before during 6MWT? 8 0 a 
Did you like the ambulation aid? 17 13
 If not, why not? Pain in arms (2) Balance problems (4)
Emotionally uncomfortable (1) Problems with placing 
 oxygen tank (1)
Can easily do without (1) Too heavy (1)
Problems with seat (1)
No reason (1)
Could you walk further with the ambulation aid compared 
 with an unaided 6MWT?
20 13 a  
 If you walk further, why? Less dyspnea (6) Less dyspnea (6)
Safer (2) More stable (2)
More stable (7) Less dyspnea and 
 more stable (2)
Less dyspnea and more stable (2) Less exhausting (2)
Less leg fatigue (1) Faster (1)
No reason (2)
Were you ashamed using the ambulation aid? 4 2
 If you were ashamed, why? Too young (3) Acceptance ambulation aid (1)
Illness is visible (1) Other aids are more convenient (1)
Would you use it in daily life? 16 8 a  
I felt safe while using the aid b 83 .5 (21.8) 75.8 (19.6)
I felt like I could fall while using the aid b 13.1 (24.7) 36.6 (33.1) a  
I felt stable while using the aid b 88.9 (18.2) 63.4 (27.9) a  
I think this is a solid ambulation aid b 93.7 (8.7) 68.8 (32.8) a  
I had confi dence in the aid during the 6MWT b  89.6 (15.1) 73.4 (33.9)
Numbers indicate positive answers. See Table 3 legend for expansion of abbreviations.
 a P  , .05 vs rollator.
 b Visual Analogue Scale score (mm ).
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